The Influence of Study Quality, Age, and Geographic Factors on Polycystic Ovary Syndrome Prevalence-A Systematic Review and Meta-Analysis (Supplemental data)

<p><strong><span>Supplemnatray data for manuscript tentatively entitled "The Influence of Study Quality, Age, and Geographic Factors on </span></strong><strong><span>Polycystic Ovary Syndrome Prevalence</span></strong><strong><span>-A Systematic Review and Meta-Analysis", including:&nbsp;</span></strong></p> <p><strong><span>Supplementary Table 1.</span></strong><span> Search strategy and its results including studies published until February 29^th of 2024.</span></p> <p><strong><span>Supplementary Table 2.</span></strong><span> The quality assessment results of studies conducted on adults based on the Polycystic ovary syndrome (PCOS) Epidemiology and Phenotype (PEP) tool. </span></p> <p><strong><span>Supplementary Table 3.</span></strong><span> The quality assessment results of studies conducted on adolescents based on <a name="_Hlk176077530"></a>the Polycystic ovary syndrome (PCOS) Epidemiology and Phenotype (PEP) tool. </span></p> <p><strong><span>Supplementary Table 4.</span></strong><span> The quality assessment results of studies conducted on mixed populations (both adults and adolescents) based on PCOS Epidemiology and Phenotype (PEP) tool. </span></p> <p><strong><span>Supplementary Figure 1 (A-D). </span></strong><span>Forest plots of global PCOS prevalence stratified by diagnostic criteria (regardless of study quality, age group, and geographic region): A) NIH, B) Rotterdam, C) AE-PCOS, D) Self-report: A) NIH, B) Rotterdam, C) AE-PCOS, D) Self-report.</span></p> <p><strong><span>Supplementary Figure 2 (A-C</span></strong><span>). Forest plots of global PCOS prevalence stratified by WHO region and diagnostic criteria (regardless of study quality and age group): A) NIH, B) Rotterdam, C) AE-PCOS.</span></p> <p><strong><span>Supplementary Figure 3 (A-C).</span></strong><span> </span><a name="_Hlk174390393"></a><span>Forest plots of PCOS prevalence stratified by diagnostic criteria and age group (adults vs. adolescent) (regardless of study quality): A) NIH, B) Rotterdam, C) AE-PCOS.</span></p> <p><strong><span>Supplementary Figure 4 (A-C).</span></strong><span> Sensitivity Analysis based on high-quality studies: Impact of individual study exclusion on pooled prevalence</span> <span>(using high-quality studies only)- A) NIH, B) Rotterdam, C) AE-PCOS.</span></p>